Home Market News <!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>J&J’s Janssen Inks Mega Licensing Deal</title> </head> <body> J&J’s Janssen Inks Mega Licensing Deal

J&J’s Janssen Inks Mega Licensing Deal J&J’s Janssen Inks Mega Licensing Deal

0
<!DOCTYPE html>
<html lang= J&J’s Janssen Inks Mega Licensing Deal J&J’s Janssen Inks Mega Licensing Deal" title=" J&J’s Janssen Inks Mega Licensing Deal J&J’s Janssen Inks Mega Licensing Deal" />

Janssen headquarters in Silicon Valley

Sundry Photography

Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech has signed a licensing deal worth up to $1.7B to develop and commercialize LegoChem Biosciences’ drug candidate LCB84.

Amazing News! Janssen will pay $100M upfront for the exclusive worldwide rights to develop and commercialize LCB84, a Trop 2 directed antibody drug conjugate, or ADC. LegoChem will also be eligible to receive an option exercise payment of $200M, various milestone payments, and tiered royalties on net sales, according to LegoChem.